— The Board of Directors and Management Remain Committed to Maximizing Shareholder Value by Executing the Company’s Strategic Plan —
4D Molecular Therapeutics Q2 EPS $(0.87) Down From $(0.28) YoY
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.87) per share. This is a 210.71 percent decrease over losses of $(0.28) per share from the same period last year.